Citations

Clear

634 citation(s) found for "Hall, A".

Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Tome, Maite , Abraham, Roselle, Balaji, Seshadri , Barth, Cheryl , Berul, Charles I. , Bos, Martijn, Cannom, David S. , Choudhury, Lubna , Concannon, Maryann, Cooper, Robert , Czosek, Richard J. , Dubin, Anne M. , Dziura, James, Eidem, Benjamin W., Etheridge, Susan P. , Geske, Jeffrey B. , Gray, Belinda , Lal, Ashwin K. , Ommen, Steven R., Saarel, Elizabeth V. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Day, Sharlene M. , Abrahms, Dominic Jr, Ashley, Euan A. , Aziz, Peter F. , Batra, Anjan S. , Ferhaan, Ahmad, Gollob, Michael J., Kanter, Ronald J. , Li, Walter, Masri, Ahmad , Murphy, Ann Mooney, Popjes, Eric , Rao, Roopa S, Rosenthal, David N. , Semsarian, Chris, Shah, Maully J. , Tardif, Jill, Towbin, Jeffrey A. , Turer, Aslan T., Bos, J. Martijn , Eidem, Benjamin, Bos, Johan M , Dubin, Anne M , Ware, James S , Geske, Jeffrey B , Tome Esteban, Maria Teresa , Gray, Belinda , Salberg, Lisa , Ho, Carolyn Y. , Dziura, James, Emery, Michael S. , Estes, N.A. Mark , Hall, Kevin D. , Harmon, Kimberly G. , James, Cynthia A. , Law, Ian H. , Li, Fangyong , Link, Mark S. , McKenna, William J. , Molossi, Silvana M , Olshansky, Brian , Saberi, Sara , Zipes, Douglas P. , Cerrone, Marina , Colan, Steven D. , Erickson, Christopher, Ferhaan, Ahmad, Johnsrude, Christopher L. , Kannankeril, Prince J. , Murphy, Ann, Nandi, Deipanjan , Pérez, Marco , Perry, James C. , Rao, Roopa, Sanatani, Shubhayan , Skinner, Jonathan R. , Webster, Gregory , Wever‐Pinzon, Omar , Wong, Timothy C.

Mayo Clinic

JAMA Cardiology | May 17, 2023 | Volume: 8 | Issue: 6 | Pages: 595

10.1001/jamacardio.2023.1042 | PMID 37195701 Get It

Importance Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. Objective To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging in vigorous activity were not more likely to have an arrhythmic event or die than those who reported nonvigorous activity. Design, Setting, and Participants This was an investigator-initiated, prospective cohort study. Participants were enrolled from May 18, 2015, to April 25, 2019, with completion in February 28, 2022. Participants were categorized according to self-reported levels of physical activity: sedentary, moderate, or vigorous-intensity exercise. This was a multicenter, observational registry with recruitment at 42 high-volume HCM centers in the US and internationally; patients could also self-enroll through the central site. Individuals aged 8 to 60 years diagnosed with HCM or genotype positive without left ventricular hypertrophy (phenotype negative) without conditions precluding exercise were enrolled. Exposures Amount and intensity of physical activity. Main Outcomes and Measures The primary prespecified composite end point included death, resuscitated sudden cardiac arrest, arrhythmic syncope, and appropriate shock from an implantable cardioverter defibrillator. All outcome events were adjudicated by an events committee blinded to the patient’s exercise category. Results Among the 1660 total participants (mean [SD] age, 39 [15] years; 996 male [60%]), 252 (15%) were classified as sedentary, and 709 (43%) participated in moderate exercise. Among the 699 individuals (42%) who participated in vigorous-intensity exercise, 259 (37%) participated competitively. A total of 77 individuals (4.6%) reached the composite end point. These individuals included 44 (4.6%) of those classified as nonvigorous and 33 (4.7%) of those classified as vigorous, with corresponding rates of 15.3 and 15.9 per 1000 person-years, respectively. In multivariate Cox regression analysis of the primary composite end point, individuals engaging in vigorous exercise did not experience a higher rate of events compared with the nonvigorous group with an adjusted hazard ratio of 1.01. The upper 95% 1-sided confidence level was 1.48, which was below the prespecified boundary of 1.5 for noninferiority. Conclusions and Relevance Results of this cohort study suggest that among individuals with HCM or those who are genotype positive/phenotype negative and are treated in experienced centers, those exercising vigorously did not experience a higher rate of death or life-threatening arrhythmias than those exercising moderately or those who were sedentary. These data may inform discussion between the patient and their expert clinician around exercise participation.
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Zarif, Talal El , Nassar, Amin H. , Adib, Elio , Fitzgerald, Bailey G. , Huang, Jiaming , Mouhieddine, Tarek H. , Rubinstein, P , Nonato, Taylor K., McKay, Rana R. , Li, Mingjia , Baiocchi, Robert A. , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazlı , Falohun, Adewunmi, Abdel‐Wahab, Noha , Diab, Adi , Bankapur, Anand, Reed, Alexandra, Kim, Chul , Arora, Aakriti, El‐Am, Edward , Abdallah, Wassim , Al‐Hader, Ahmad, Ghazal, Batool Abu, Drolen, Claire , Drakaki, Alexandra , Baena, Javier , Nebhan, Caroline A. , Haykal, Tarek , Morse, Michael A. , Cortellini, Alessio , Pinato, David J. , Pria, Alessia Dalla , Bakalov, Veli , Bahary, Nathan , Rajkumar, Aarthi , Mangla, Ankit , Singh, Parminder , Nana, Frank Aboubakar , Lopetegui‐Lia, Nerea , Dobbs, Ryan W. , Funchain, Pauline , Long, Georgina V. , Genova, Carlo , Barletta, Giulia, Idossa, Damé , Lamberti, Giuseppe , Freeman, Dory , Chiao, Elizabeth Y. , Johnson, Douglas B. , Ramaswami, Ramya , Bower, Mark , Emu, Brinda , Baden, Lindsey R. , Sonpavde, Guru , Naqash, Abdul Rafeh , El Zarif, Talal , Rubinstein, Paul G , Mittra, Arjun , Owen, Dwight H , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazli , Abdel-Wahab, Noha , Diab, Adi , Kim, Chul , Shah, Neil J , Kozaily, Elie , Abdallah, Wassim , Saeed, Anwaar , Drolen, Claire , Lechner, Melissa G , Drakaki, Alexandra , Nebhan, Caroline A , Haykal, Tarek , Cortellini, Alessio , Pinato, David J , Dalla Pria, Alessia , Hall, Evan , Bahary, Nathan , Mangla, Ankit , Shah, Vishal , Aboubakar Nana, Frank , Lopetegui-Lia, Nerea , Dima, Danai , Dobbs, Ryan W , Funchain, Pauline , Woodford, Rachel , Long, Georgina V , Menzies, Alexander M , Genova, Carlo , Puri, Sonam , Florou, Vaia , Lamberti, Giuseppe , Addeo, Alfredo , Bersanelli, Melissa , Xie, Wanling , Reid, Erin G , Chiao, Elizabeth Y , Sharon, Elad , Johnson, Douglas B , Ramaswami, Ramya , Bower, Mark , Choueiri, Toni K , Lurain, Kathryn , Sonpavde, Guru , Naqash, Abdul Rafeh , Nassar, Amin H. , Singh, Parminder , Saeed, Anwaar , Shah, Vishal , Dima, Danai , Saleem, Rabia, Saponara, Maristella , Queirolo, Paola , Addeo, Alfredo , Xie, Wanling , Sharon, Elad , Marron, Thomas , Choueiri, Toni K. , Espinar, Javier Baena

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 21 | Pages: 3712-3723

10.1200/jco.22.02459 | PMID 37192435 Get It

PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.
Trends in Patch Testing with the Mayo Clinic Standard Series, 2017–2021
Zawawi, Suha, Yang, Yul W. , Drage, Lisa A., Youssef, Molly J. , Yiannias, James A. , Davis, Mark D.P. , Hall, Matthew R. , Cantwell, Hafsa M. , Hall, Matthew R

Mayo Clinic

Dermatitis® | May 16, 2023 | Volume: 34 | Issue: 5 | Pages: 405-412

10.1089/derm.2023.0063 | PMID 37192467 Get It

Background: Patch testing to a standard series is used to identify culprit allergens in patients with contact dermatitis. The reaction rates evolve over time based on trends in cutaneous exposures by the general population. Objective: The aim of this study was to analyze the patch test results of the Mayo Clinic standard series in patients tested from 2017 to 2021. Methods: The patch test reactions of standard series allergens tested from 2017 to 2021 were retrospectively reviewed and compared with the results of our prior report from 2011 to 2015 as well as the North American Contact Dermatitis Group (NACDG) report from 2017 to 2018. Results: Of 2667 patients tested, 1683 (63.1%) had at least 1 positive reaction. The 15 allergens with the highest reaction rates were hydroperoxides of linalool 1%, nickel (II) sulfate hexahydrate, methylisothiazolinone, Myroxylon pereirae resin, hydroperoxides of linalool 0.5%, methyldibromo glutaronitrile, neomycin sulfate, cobalt (II) chloride hexahydrate, fragrance mix I, benzalkonium chloride, bacitracin, hydroperoxides of limonene, methylchloroisothiazolinone/methylisothiazolinone, p-phenylenediamine, and textile dye mix. Twelve (80%) of these allergens were also in the top 15 of the most recent NACDG report. Conclusions: Hydroperoxides of linalool and hydroperoxides of limonene are new allergens that have been added to our standard series. These are associated with high reaction rates.
Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research
Taylor, Jack C. , Heuer, Hilary W. , Clark, Annie L , Wise, Amy B. , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rao, Meghana , Brushaber, Daniell, Kramer, Joel H. , Welch, Ariane E., Kornak, John , Kremers, Walter K. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hall, Matthew , Huey, Edward D. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Rankin, Katherine P. , Ratnasiri, Buddhika , Wong, Bonnie , Gorno‐Tempini, Maria Luisa , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Taylor, Jack Carson , Staffaroni, Adam M , Pascual, Belen , Kremers, Walter K , Domoto-Reilly, Kimiko , Brushaber, Danielle , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Irwin, David J. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Nevler, Naomi , Rojas, Julio C. , Tartaglia, Maria Carmela , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 10, 2023 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/dad2.12423 | PMID 37180971 Get It

AbstractIntroductionRemote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD‐mApp).MethodsA diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC‐FTLD = 0 [N = 101]; prodromal: 0.5 [N = 49]; symptomatic ≥1 [N = 51]; not measured [N = 13]) were asked to complete ALLFTD‐mApp tests on their smartphone three times within 12 days. They completed smartphone familiarity and participation experience surveys.ResultsIt was feasible for participants to complete the ALLFTD‐mApp on their own smartphones. Participants reported high smartphone familiarity, completed ∼ 70% of tasks, and considered the time commitment acceptable (98% of respondents). Greater disease severity was associated with poorer performance across several tests.DiscussionThese findings suggest that the ALLFTD‐mApp study protocol is feasible and acceptable for remote FTD research.HIGHLIGHTS The ALLFTD Mobile App is a smartphone‐based platform for remote, self‐administered data collection. The ALLFTD Mobile App consists of a comprehensive battery of surveys and tests of executive functioning, memory, speech and language, and motor abilities. Remote digital data collection using the ALLFTD Mobile App was feasible in a multicenter research consortium that studies FTD. Data was collected in healthy controls and participants with a range of diagnoses, particularly FTD spectrum disorders. Remote digital data collection was well accepted by participants with a variety of diagnoses.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Altman, Jessica K. , Bixby, Dale L. , Fathi, Amir T. , Foran, James M. , Gojo, Ivana , Hall, Aric C. , Maness, Lori J., Mangan, James K. , Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey , Ali, Moaath K. Mustafa , Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Percival, Mary-Elizabeth, Perl, Alexander E. , Rao, Dinesh S. , Shallis, Rory M. , Shami, Paul J. , Stein, Eytan M. , Stone, Richard M. , Sweet, Kendra , Uy, Geoffrey L. , Vachhani, Pankit , Cassara, Carly J., Freedman-Cass, Deborah A., Stehman, Katie, Uy, Geoffrey , Pollyea, Daniel Aaron , Jonas, Brian A. , Kishtagari, Ashwin , Lancet, Jeffrey E. , Mims, Alice S , Przespolewski, Amanda , Ravandi, Farhad , Thota, Swapna

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2023 | Volume: 21 | Issue: 5 | Pages: 503-513

10.6004/jnccn.2023.0025 | PMID 37156478 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.
Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer
Eriksson, Mikael , Vachon, Celine M. , Conant, Emily F. , Hall, Per , Vachon, Celine M. , Conant, Emily F , Hall, Per N , Eriksson, Mikael , Czene, Kamila

Mayo Clinic

Journal of Clinical Oncology | March 17, 2023 | Volume: 41 | Issue: 14 | Pages: 2536-2545

10.1200/jco.22.01564 | PMID 36930854 Get It

PURPOSE Image-derived artificial intelligence–based short-term risk models for breast cancer have shown high discriminatory performance compared with traditional lifestyle/familial-based risk models. The long-term performance of image-derived risk models has not been investigated. METHODS We performed a case-cohort study of 8,604 randomly selected women within a mammography screening cohort initiated in 2010 in Sweden for women age 40-74 years. Mammograms, age, lifestyle, and familial risk factors were collected at study entry. In all, 2,028 incident breast cancers were identified through register matching in May 2022 (206 incident breast cancers were found in the subcohort). The image-based model extracted mammographic features (density, microcalcifications, masses, and left-right breast asymmetries of these features) and age from study entry mammograms. The Tyrer-Cuzick v8 risk model incorporates self-reported lifestyle and familial risk factors and mammographic density to estimate risk. Absolute risks were estimated, and age-adjusted AUC model performances (aAUCs) were compared across the 10-year period. RESULTS The aAUCs of the image-based risk model ranged from 0.74 (95% CI, 0.70 to 0.78) to 0.65 (95% CI, 0.63 to 0.66) for breast cancers developed 1-10 years after study entry; the corresponding Tyrer-Cuzick aAUCs were 0.62 (95% CI, 0.56 to 0.67) to 0.60 (95% CI, 0.58 to 0.61). For symptomatic cancers, the aAUCs for the image-based model were ≥0.75 during the first 3 years. Women with high and low mammographic density showed similar aAUCs. Throughout the 10-year follow-up, 20% of all women with breast cancers were deemed high-risk at study entry by the image-based risk model compared with 7.1% using the lifestyle familial-based model ( P < .01). CONCLUSION The image-based risk model outperformed the Tyrer-Cuzick v8 model for both short-term and long-term risk assessment and could be used to identify women who may benefit from supplemental screening and risk reduction strategies.
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
Karrison, Theodore , Pisansky, Thomas M. , Posadas, Edwin M. , Hall, William A. , Rodgers, Joseph P., Feng, Felix Y. , Koontz, Bridget F. , Ballas, Leslie , Berlin, Alejandro , Tran, Phuoc T , O'Daniel, Jennifer C , Hope, Thomas A.

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: TPS283-TPS283

10.1200/jco.2023.41.6_suppl.tps283 Get It

TPS283 Background: There is no clear standard of care for biochemically recurrent prostate cancer (PCa) with positron emission tomography (PET)-detected oligometastases and normal conventional imaging (CIM). Phase II trials show that stereotactic ablative body radiotherapy (SABR) to oligometastases may delay cancer progression and initiation of androgen deprivation therapy (ADT) and its untoward effects. ADT with radiation prolongs survival in locally advanced PCa and in CIM metastatic PCa. However, there is a knowledge gap about timing and benefit vs toxicity of ADT with SABR in early oligometastatic PCa. NRG GU011 (PROMETHEAN) is a randomized phase II trial of SABR with or without relugolix for early PET-detected recurrent oligometastatic PCa. This study aims to evaluate the impact of relugolix, a novel oral gonadotropin-releasing hormone receptor antagonist, when combined with SABR to oligometastases. Relugolix allows for rapid testosterone recovery and is associated with fewer cardiovascular events when compared to leuprolide and is hypothesized to have low late ADT toxicity. GU011 will provide patients and their physicians data on the relative risks and benefits of early or delayed ADT in this setting. Methods: NRG-GU011 NCT# 05053152 is a randomized phase II double-blinded, placebo-controlled trial with randomization to SABR + 6 months placebo vs SABR + 6 months relugolix. Eligible patients have biochemical recurrence after prior curative intent radiation or surgery for localized PCa, PSA < 10 ng/mL, negative CIM and 1-5 PET-evident metastases (≥1 extrapelvic). SABR is delivered in 1-5 fractions to BED >100 Gy1.5, followed by placebo or relugolix 120mg daily for 6 months. Patients will then be followed with imaging at time of biochemical recurrence. The planned sample size of 260 patients (130 per arm) will provide 85% power to detect a hazard ratio of 0.65 for radiographic progression-free survival (rPFS), based on a one-sided test at alpha 0.10. Planned enrollment is predicted at 8 patients per month with an estimated study completion date of late 2026. The primary endpoint is CIM rPFS. Secondary endpoints include PET-based rPFS, sexual and hormonal quality of life (QoL) assessed by EPIC-26, other QoL measures from EQ5D-5L, EORTC QLQ-30 and PROMIS Fatigue, and between-group comparisons of time to salvage therapy, castration-resistance, local progression (SABR-targeted lesion), biochemical progression, distant metastases, prostate cancer-specific mortality, metastasis-free survival, and overall survival. We also aim to determine adverse event rates for both treatment arms and evaluate genomic and blood markers of treatment response. This study opened in December 2021. Clinical trial information: NCT05053152 .
MT‐ATP6 mitochondrial disease identified by newborn screening reveals a distinct biochemical phenotype
Tise, Christina G. , Verscaj, Courtney P. , Mendelsohn, Bryce A. , Woods, Jeremy D. , Lee, Chung U. , Enns, Gregory M. , Stander, Zinandré, Cowan, Tina M. , Cusmano‐Ozog, Kristina , Hall, Patricia

Mayo Clinic

American Journal of Medical Genetics Part A | March 8, 2023 | Volume: 191 | Issue: 6 | Pages: 1492-1501

10.1002/ajmg.a.63159 | PMID 36883293 Get It

AbstractAlthough decreased citrulline is used as a newborn screening (NBS) marker to identify proximal urea cycle disorders (UCDs), it is also a feature of some mitochondrial diseases, including MT‐ATP6 mitochondrial disease. Here we describe biochemical and clinical features of 11 children born to eight mothers from seven separate families who were identified with low citrulline by NBS (range 3–5 μM; screening cutoff >5) and ultimately diagnosed with MT‐ATP6 mitochondrial disease. Follow‐up testing revealed a pattern of hypocitrullinemia together with elevated propionyl‐(C3) and 3‐hydroxyisovaleryl‐(C5‐OH) acylcarnitines, and a homoplasmic pathogenic variant in MT‐ATP6 in all cases. Single and multivariate analysis of NBS data from the 11 cases using Collaborative Laboratory Integrated Reports (CLIR; https://clir.mayo.edu) demonstrated citrulline <1st percentile, C3 > 50th percentile, and C5‐OH >90th percentile when compared with reference data, as well as unequivocal separation from proximal UCD cases and false‐positive low citrulline cases using dual scatter plots. Five of the eight mothers were symptomatic at the time of their child(ren)'s diagnosis, and all mothers and maternal grandmothers evaluated molecularly and biochemically had a homoplasmic pathogenic variant in MT‐ATP6, low citrulline, elevated C3, and/or elevated C5‐OH. All molecularly confirmed individuals (n = 17) with either no symptoms (n = 12), migraines (n = 1), or a neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) phenotype (n = 3) were found to have an A or U mitochondrial haplogroup, while one child with infantile‐lethal Leigh syndrome had a B haplogroup.
Community-Onset Bacterial Coinfection in Children Critically Ill With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
酒井, 忠雄, Nakamura, Mari M, Young, Cameron C, Newhams, Margaret M, Halasa, Natasha B, Reed, J Nelson, Fitzgerald, Julie C, Spinella, Philip C, Soma, Vijaya L, Walker, Tracie C, Loftis, Laura L, Maddux, Aline B, Kong, Michele, Rowan, Courtney M, Hobbs, Charlotte V, Schuster, Jennifer E, Riggs, Becky J, McLaughlin, Gwenn E, Michelson, Kelly N, Hall, Mark W, Babbitt, Christopher J, Cvijanovich, Natalie Z, Zinter, Matt S, Maamari, Mia, Schwarz, Adam J, Singh, Aalok R, Flori, Heidi R, Gertz, Shira J, Staat, Mary A, Giuliano, John S, Hymes, Saul R, Clouser, Katharine N, McGuire, John, Carroll, Christopher L, Thomas, Neal J, Levy, Emily R, Randolph, Adrienne G, Randolph, Adrienne G. , Spinella, Philip C. , Levy, Emily R. , Staat, Mary Allen , Young, Cameron C. , McGuire, John K. , Gertz, Shira J. , Kong, Michele , Zinter, Matt S. , Moffitt, Kristin , Malloch, Lacy , Moffitt, Kristin L , Young, Cameron C , Hobbs, Charlotte V , Randolph, Adrienne G , Levy, Emily R , Spinella, Philip C , Kong, Michele , Staat, Mary A , Gertz, Shira J , Nakamura, Mari M, Newhams, Margaret M, Halasa, Natasha B, Reed, J Nelson, Fitzgerald, Julie C, Spinella, Philip C, Soma, Vijaya L, Walker, Tracie C, Loftis, Laura L, Maddux, Aline B, Kong, Michele, Rowan, Courtney M, Schuster, Jennifer E, Riggs, Becky J, McLaughlin, Gwenn E, Michelson, Kelly N, Hall, Mark W, Babbitt, Christopher J, Cvijanovich, Natalie Z, Zinter, Matt S, Maamari, Mia, Schwarz, Adam J, Singh, Aalok R, Flori, Heidi R, Gertz, Shira J, Staat, Mary A, Giuliano, John S, Hymes, Saul R, Clouser, Katharine N, McGuire, John, Carroll, Christopher L, Thomas, Neal J, Levy, Emily R

Mayo Clinic

Open Forum Infectious Diseases | March 7, 2023 | Volume: 10 | Issue: 3 | Pages: No page available

10.1093/ofid/ofad122 | PMID 36968962 Get It

AbstractBackgroundCommunity-onset bacterial coinfection in adults hospitalized with coronavirus disease 2019 (COVID-19) is reportedly uncommon, though empiric antibiotic use has been high. However, data regarding empiric antibiotic use and bacterial coinfection in children with critical illness from COVID-19 are scarce.MethodsWe evaluated children and adolescents aged &lt;19 years admitted to a pediatric intensive care or high-acuity unit for COVID-19 between March and December 2020. Based on qualifying microbiology results from the first 3 days of admission, we adjudicated whether patients had community-onset bacterial coinfection. We compared demographic and clinical characteristics of those who did and did not (1) receive antibiotics and (2) have bacterial coinfection early in admission. Using Poisson regression models, we assessed factors associated with these outcomes.ResultsOf the 532 patients, 63.3% received empiric antibiotics, but only 7.1% had bacterial coinfection, and only 3.0% had respiratory bacterial coinfection. In multivariable analyses, empiric antibiotics were more likely to be prescribed for immunocompromised patients (adjusted relative risk [aRR], 1.34 [95% confidence interval {CI}, 1.01–1.79]), those requiring any respiratory support except mechanical ventilation (aRR, 1.41 [95% CI, 1.05–1.90]), or those requiring invasive mechanical ventilation (aRR, 1.83 [95% CI, 1.36–2.47]) (compared with no respiratory support). The presence of a pulmonary comorbidity other than asthma (aRR, 2.31 [95% CI, 1.15–4.62]) was associated with bacterial coinfection.ConclusionsCommunity-onset bacterial coinfection in children with critical COVID-19 is infrequent, but empiric antibiotics are commonly prescribed. These findings inform antimicrobial use and support rapid de-escalation when evaluation shows coinfection is unlikely.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Morra, Anna , Andrulis, Irene L. , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Daly, Mary B., Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Howell, Anthony , Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, Johnson, Nichola , Kristensen, Vessela N. , Lindblom, Annika , Mannermaa, Arto , Mavroudis, Dimitrios, Nevelsteen, Ines, Neven, Patrick , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Phillips, Kelly‐Anne , Plaseska-Karanfilska, Dijana, Rack, Brigitte , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Adank, Muriel A. , Hooning, Maartje J. , Eccles, Diana , Plaseska‐Karanfilska, Dijana , Eccles, Diana , Evans, D Gareth , García-Closas, Montserrat , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Schreurs, Maartje A. C. , Anton‐Culver, Hoda , Augustinsson, Annelie , Behrens, Sabine , Bojesen, Stig E. , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Dennis, Joe , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Graßmann, Felix , Hartikainen, Jaana M. , Hopper, John L. , Houlston, Richard S. , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Jones, Michael E. , Kurian, Allison W. , Lambrechts, Diether , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mulligan, Anna Marie , Muranen, Taru , Nevanlinna, Heli , Newman, William G. , Olshan, Andrew F. , Peterlongo, Paolo , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Romero, Atocha , Saloustros, Emmanouil , Scott, Christopher, Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Pharoah, Paul D.P. , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

No container title available | February 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2569372/v1 | PMID 36824750 Get It

Abstract Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09–1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words)